

Diphtheria Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/D268B11FF67EN.html>

Date: August 2018

Pages: 60

Price: US\$ 1,200.00 (Single User License)

ID: D268B11FF67EN

Abstracts

Diphtheria Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Diphtheria pipeline products.

DISEASE OVERVIEW

Global Diphtheria market is estimated to be around \$4.5 billion in 2020 driven by the US spending. 16 companies are currently active in development of vaccines and treatment options for Diphtheria worldwide. 21 therapeutic candidates are in various stages of pre-clinical/ discovery or clinical trials (phase 1, phase 2, phase 3) stages.

Diphtheria is one of the key areas of focus among infectious disease pipeline. Diphtheria is caused by *Corynebacterium diphtheria*, which produce exotoxins and the primary areas infected in humans are throat and upper airways.

Typical symptoms extend from sore throat, mild fever together with swollen glands inside throat in mild cases. In serious conditions, it can result in myocarditis or peripheral neuropathy.

Despite wide administration of vaccines (bacterial toxoid) against Diphtheria in most countries, children in low income countries continue to be largely affected. Currently, 16 companies are actively participating in developing vaccines and cure for Diphtheria worldwide. The Diphtheria pipeline companies include Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Boryung Pharmaceutical Co Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi SA, Serum Institute of India Ltd, Shantha Biotechnics Pvt Ltd, Tianjin CanSino Biotechnology Inc and Wockhardt Ltd.

REPORT DESCRIPTION

The Diphtheria pipeline guide presents complete overview of drugs currently being developed for Diphtheria. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Diphtheria pipeline candidate.

Research and Development progress along with latest news related to each of the Diphtheria pipeline candidates is included.

Major companies participating in therapeutic development of Diphtheria are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Diphtheria from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Diphtheria clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Diphtheria pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF DIPHTHERIA PIPELINE REPORT INCLUDES

Panorama of Diphtheria pipeline markets including statistics on therapeutic drugs and companies involved

Diphtheria Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Diphtheria pipeline candidates across various 'Mechanism of Actions' are also

presented in the study

Overview of companies participating in Diphtheria pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Diphtheria pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Diphtheria pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Diphtheria pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Diphtheria Pipeline include-
 - Number of Companies with Diphtheria projects in pre-clinical Development-
 - Number of Companies with Diphtheria projects in Clinical Development-
 - Diphtheria Pipeline Companies based in Americas
 - Diphtheria Pipeline Companies based in Europe
 - Diphtheria Pipeline Companies based in Asia Pacific
 - Diphtheria Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
 - Diphtheria Pipeline Agents in pre- clinical/Discovery stage of Development
 - Diphtheria Pipeline Agents in Clinical Development stage
 - Diphtheria Pipeline Therapeutic Compounds received special status
 - Mechanism of Action of most pipeline Drugs-
 - Small molecules among the Diphtheria Pipeline agents

II. INSIGHTS INTO DIPHTHERIA PIPELINE

1. Disease Overview
 - Introduction to Diphtheria
 - Symptoms and Causes of Diphtheria
 - Treatment or Prevention Options for Diphtheria
 - Other Details
2. Phase wise Pipeline Compounds
 - Diphtheria Pipeline- Pre- Clinical/Discovery stage Drugs
 - Diphtheria Pipeline- Phase 1 stage Drugs
 - Diphtheria Pipeline- Phase 2 stage Drugs
 - Diphtheria Pipeline- Phase 3 stage Drugs
 - Diphtheria Pipeline- Pre-Registration stage Drugs
3. Company wise Diphtheria Pipeline Compounds
4. Diphtheria Pipeline by Mechanism of Action

III. DIPHTHERIA PIPELINE COMPOUND DETAILS

DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
DTcP vaccine

BK1310

(BVN-002, DTaP-IPV) combination vaccine

Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine

VN-0105

GC3111A

(diphtheria, tetanus, acellular pertussis, hepatitis B recombinant, poliomyelitis, haemophilus influenza type B) vaccine

DPT-H-HiB pentavalent vaccine

LBVD vaccine

s315

Adsorbed Acellular Pertussis (tricomponent) vaccine

Adsorbed Acellular Pertussis (tricomponent) vaccine

(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine

Adacel+ Tdap booster

(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine

DTaP Vaccine

DTwP-HepB-Hib-IPV vaccine

DTcP vaccine

vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. DIPHTHERIA PIPELINE COMPANY BRIEFS

Beijing Minhai Biotechnology Co Ltd

BIKEN Corporation

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd
Daiichi Sankyo Company
GC Pharma- Korea
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Limited
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi SA
Sanofi Pasteur SA
Serum Institute of India
Shantha Biotechnics Pvt Ltd
Tianjin CanSino Biotechnology Inc
Wockhardt Ltd

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL DIPHTHERIA PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Diphtheria Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/D268B11FF67EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D268B11FF67EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970